Showing results (131-140 of 350) with videos related to
Sort By:
Pageof 35
Neurology|April 1, 1988
No response to high-dose muscarinic agonist therapy in Alzheimer's diseaseM M Mouradian, E Mohr, J A Williams, et al.Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 1993
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980D Bravi, T L Davis, M M Mouradian, et al.European Journal of Pharmacology|September 24, 1982
Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsyS L Cohen, M Knight, C A Tamminga, et al.Brain Research|December 24, 1991
Regional cerebral glucose metabolism compared in rodents and humansJ Blin, C A Ray, T N Chase, et al.Brain Research|January 21, 2000
Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrainJ D Oh, K Chartisathian, T N Chase, et al.Archives of Neurology|July 1, 1986
Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86G Bruno, E Mohr, M Gillespie, et al.Brain Research|May 29, 1992
Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalinT M Engber, R C Boldry, S Kuo, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 1, 1987
Cognitive concomitants of dopamine system stimulation in parkinsonian patientsE Mohr, G Fabbrini, S Ruggieri, et al.Journal of Clinical and Experimental Neuropsychology|March 1, 1990
Impairment of central auditory function in Alzheimer's diseaseE Mohr, C Cox, J Williams, et al.European Journal of Pharmacology|April 9, 1986
Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactionsP Barone, T A Davis, A R Braun, et al.Pageof 35